Insight Molecular Diagnostics Inc. (IMDX) held its Q4 2025 earnings conference call to review financial results and strategic developments. The session featured prepared remarks followed by a question-and-answer period with analysts.
Participants
Company Executives
- Joshua Riggs – President, CEO & Director
- Andrea James – Chief Financial Officer
- Ekkehard Schutz – Chief Science Officer
Conference Call Analysts
- Thomas Flaten – Lake Street Capital Markets, LLC, Research Division
- Michael Matson – Needham & Company, LLC, Research Division
- Benjamin Mee – Stephens Inc., Research Division
Opening Remarks
Senior Executive Assistant Gabrielle Woody welcomed attendees and highlighted the comprehensive shareholder letter available on the Investor Relations page at investors.imdxinc.com. She explained that the call expands on details from that document.
Woody introduced the leadership team, including President and CEO Josh Riggs, Chief Science Officer Ekke Schutz, and CFO Andrea James. Analysts joined as panelists for the Q&A segment after the main presentation.
Safe Harbor Statement
Woody outlined the safe harbor provisions, noting that forward-looking statements about future events fall under the Private Securities Litigation Reform Act of 1995. Investors should consult recent SEC filings, such as the latest Form 10-K and Forms 10-Q, for risks that could impact actual results.
These statements represent views only as of the call date, and the company holds no duty to revise them.
With formalities complete, Woody handed the call to President and CEO Josh Riggs to begin the discussion.
